Wednesday, March 17, 2021 Antibody-Mediated HIV Prevention Studies Results Published in Peer-Reviewed Journal Credit: HIV Vaccine Trials Network Intravenous infusions of an investigational anti-HIV antibody safely prevented acquisition of HIV strains sensitive to that antibody, but did not significantly reduce overall HIV acquisition among participants in two NIAID-sponsored clinical trials, according to a report published today in the New England Journal of Medicine. Results from these trials, known as the Antibody-Mediated Prevention (AMP) Studies, were first presented in January 2021 during the 4th HIV Research for Prevention Conference (HIV R4P). Insights gleaned from the AMP data lay the foundation for future development of long-acting antibody-based HIV prevention tools and, ultimately, an HIV vaccine. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107